No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC ...Middle East

Medscape - News
In fact, the worst survival outcomes were seen with the most commonly used first-line regimen, FOLFOX chemotherapy plus the VEGF inhibitor bevacizumab. Medscape Medical News

Hence then, the article about no survival benefit for upfront vegf inhibitors in metastatic crc was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( No Survival Benefit for Upfront VEGF Inhibitors in Metastatic CRC )

Apple Storegoogle play

Last updated :

Also on site :



Latest News